ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” first quarter 2025 ...

Shares of AbbVie Inc. ABBV slid 3.14% to $174.20 Thursday, on what proved to be an all-around dismal trading session for the ...

Investing isn’t easy, and given the current market volatility, retail investors are on edge, worrying about their portfolios.

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

A significant trading signal occurred for AbbVie stock at $164.86, ahead of tariff reversal news. ABBV climbed up to 9.2% ...

The Allegations: Rosen Law Firm is Investigating the Allegations that Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Misled Investors Regarding its Business Operations.

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

Shares of AbbVie Inc. ABBV slid 5.83% to $175.67 Tuesday, on what proved to be an all-around poor trading session for the ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held the top spot, the total impressions dipped by 2 million from when Sanofi ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) dropped 0.2% during trading on Thursday after an insider sold shares in the company. The stock traded as low as $204.55 and last traded at $204.69.

Learn more about whether Halozyme Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.